PanOptica
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
290 Mountain Home Rd, Woodside, Californ...Phone Number
(908) 766-2202Website
www.panopticapharma.comRevenue
$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About PanOptica
PanOptica, Inc., is a private biopharmaceutical company focused on developing innovative ophthalmology therapies. Investors include Third Rock Ventures and SV Health Investors. The company was co-founded by Paul Chaney, past President of OSI-Eyetech, and Martin Wax, MD, most recently Vice President of Research and Development and Head of Ophthalmology Discovery and Pre-clinical Development at Alcon Labs, Inc. The company seeks early-stage assets translated from other diseases and develops select candidates through human clinical proof of concept.Explore more
PanOptica Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PanOptica your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if PanOptica has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when PanOptica launches new products
Click to see if PanOptica had a recent Job posting/layoffs
Earning: See what the market has to say on PanOptica recently announced quarterly report
PanOptica, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once PanOptica has new funding data
Check out if PanOptica is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at PanOptica
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to PanOptica
Compare insights from companies similar to PanOptica, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
PanOptica
$5M
1-10
Private
$75M
2009
MW
Martin WaxChief Marketing Officer & Executive VP, Research & Development
Company Profile Activity
Activity Insights
PanOptica is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
PanOptica is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about PanOptica.
PanOptica financials insights
Gather financial insights about PanOptica, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$30M
2014
Series B
$45M
PanOptica Tech Stack
A closer look at the technologies used by PanOptica
Most Recent Scoops
Funding
Funding
Funding
PanOptica recently secured $23.88 million in a Series B funding round. Novo Ventures, and Third Rock Ventures led the investment.
Funding
Funding
PanOptica recently secured an undisclosed amount of capital in a Series B funding round.
Funding
Funding
PanOptica News & Media
PanOptica Announces Licensing Agreement with Zhaoke Ophthalmology for PAN-90806 for the Treatment of Neovascular Eye Diseases in China, South Korea, and Southeast Asia
MOUNT ARLINGTON, N.J.--(BUSINESS WIRE)--PanOptica confirms the licensing agreement with Zhaoke Ophthalmology to develop and commercialize PAN-90806 in China, South Korea, and Southeast Asia.PanOptica Anti-VEGF Eye Drop Shows Promise in Treatment of Neovascular (Wet) AMD
MOUNT ARLINGTON, N.J.--(BUSINESS WIRE)--PanOptica reported positive and unprecedented clinical data for PAN-90806, a once-daily topical eye drop, at OIS@AAO.PanOptica to Present Positive Topical Anti-VEGF Eye Drop Data at OIS@AAO
MOUNT ARLINGTON, N.J.--(BUSINESS WIRE)--PanOptica announced that the company will present topline data from its Phase 1/2 clinical trial of PAN-90806 at the OIS@AAO on Thurs., Oct. 10, 2019
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding PanOptica
Sign Up For FreeTo access detailed company insights
PanOptica, Inc., is a private biopharmaceutical company focused on developing innovative ophthalmology therapies. Investors include Third Rock Ventures and SV Health Investors. The company was co-founded by Paul Chaney, past President of OSI-Eyetech, and Martin Wax, MD, most recently Vice President of Research and Development and Head of Ophthalmol... Read More
